Literature DB >> 25220468

Prospective validation of Baveno V definitions and criteria for failure to control bleeding in portal hypertension.

Sun Young Ahn1, Soo Young Park, Won Young Tak, Yu Rim Lee, Eun Jeong Kang, Jung Gil Park, Won Kee Lee, Kwan Lee, Young Oh Kweon.   

Abstract

UNLABELLED: New definitions and criteria were released at the Baveno V consensus meeting. The purposes of this study were to verify Baveno V definitions and criteria for failure to control bleeding and to determine the usefulness of the combined use of the Adjusted Blood Requirement Index [ABRI: (number of blood units)/(final hematocrit-initial hematocrit)+0.01] with Baveno V criteria. In all, 246 consecutive liver cirrhosis patients with acute bleeding associated with portal hypertension were enrolled prospectively between January 2010 and October 2012. The treatment outcome on day 5 was assessed by endoscopy. For the ABRI calculation, two hematocrit levels were used as the initial hematocrit: the first level measured upon patient arrival (ABRI-A) and the lowest level measured before transfusion (ABRI-B). Treatment failures were identified in 53 patients, of whom 24 died. Based on repeated endoscopic findings, 29 patients were identified as treatment failures, while according to Baveno V criteria, 47 patients were regarded as treatment failures. The area under the receiver operating characteristic curve (AUROC) of Baveno V criteria was 0.906, and the sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio, and negative likelihood ratio were 83.0%, 98.4%, 93.6%, 95.5%, 53.41, and 0.17, respectively. The AUROC of Baveno V criteria was significantly greater than those of Baveno IV (P=0.0001) and Baveno II/III (P<0.0001) criteria. Adding ABRI-A or -B to Baveno V criteria resulted in a significant reduction of the AUROC (P<0.05).
CONCLUSION: The Baveno V criteria are good predictors of treatment failure of early-stage acute gastrointestinal bleeding in patients with portal hypertension, while the addition of ARBI does not improve the prediction accuracy of the outcome of bleeding.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2015        PMID: 25220468     DOI: 10.1002/hep.27441

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  6 in total

Review 1.  Molecular prognostic prediction in liver cirrhosis.

Authors:  Nicolas Goossens; Shigeki Nakagawa; Yujin Hoshida
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

Review 2.  Management of Refractory Variceal Bleed in Cirrhosis.

Authors:  Gajanan A Rodge; Usha Goenka; Mahesh K Goenka
Journal:  J Clin Exp Hepatol       Date:  2021-09-04

3.  U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients.

Authors:  Dhiraj Tripathi; Adrian J Stanley; Peter C Hayes; David Patch; Charles Millson; Homoyon Mehrzad; Andrew Austin; James W Ferguson; Simon P Olliff; Mark Hudson; John M Christie
Journal:  Gut       Date:  2015-04-17       Impact factor: 23.059

4.  Medical expenses in treating acute esophageal variceal bleeding: A 15-year nationwide population-based cohort study.

Authors:  Chueh-Ling Liu; Cheng-Kun Wu; Hon-Yi Shi; Wei-Chen Tai; Chih-Ming Liang; Shih-Cheng Yang; Keng-Liang Wu; Yi-Chun Chiu; Seng-Kee Chuah
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

5.  Clinical Factors Associated with Mortality in Cirrhotic Patients Presenting with Upper Gastrointestinal Bleeding.

Authors:  Kirles Bishay; Parul Tandon; Stacey Fisher; Dominique Yelle; Ian Carrigan; Krista Wooller; Erin Kelly
Journal:  J Can Assoc Gastroenterol       Date:  2019-03-10

6.  The role of a multidisciplinary team in the management of portal hypertension.

Authors:  Yujen Tseng; Lili Ma; Minzhi Lv; Tiancheng Luo; Chengfeng Liu; Yichao Wei; Chu Liu; Ji Zhou; Zhiping Yan; Pengju Xu; Guohua Hu; Hong Ding; Yuan Ji; Shiyao Chen; Jian Wang
Journal:  BMC Gastroenterol       Date:  2020-04-03       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.